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Abstract
Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are progressive multisystemic disorders caused by similar mutations at
two different genetic loci. The common key feature of DM pathogenesis is nuclear accumulation of mutant RNA which
causes aberrant alternative splicing of specific pre-mRNAs by altering the functions of two RNA binding proteins, MBNL1
and CUGBP1. However, DM1 and DM2 show disease-specific features that make them clearly separate diseases suggesting
that other cellular and molecular pathways may be involved. In this study we have analysed the histopathological, and
biomolecular features of skeletal muscle biopsies from DM1 and DM2 patients in relation to presenting phenotypes to
better define the molecular pathogenesis. Particularly, the expression of CUGBP1 protein has been examined to clarify if this
factor may act as modifier of disease-specific manifestations in DM. The results indicate that the splicing and muscle
pathological alterations observed are related to the clinical phenotype both in DM1 and in DM2 and that CUGBP1 seems to
play a role in classic DM1 but not in DM2. In conclusion, our results indicate that multisystemic disease spectrum of DM
pathologies may not be explained only by spliceopathy thus confirming that the molecular pathomechanism of DM is more
complex than that actually suggested.
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Introduction
Myotonic dystrophy (DM) is the most common adult onset
muscular dystrophy affecting mainly skeletal muscle, heart, and
the central nervous system [1]. Two DM loci are associated with
two types of the disease. DM type 1 (DM1) is caused by the
expansion of an unstable CTG trinucleotide repeat in the 39
untranslated region of the DM protein kinase (DMPK) gene [2,3].
The DM type 2 (DM2) mutation consists in the expansion of an
unstable CCTG tetranucleotide within the first intron of the
CCHC-type zinc finger, nucleic acid-binding protein (CNBP) gene
(previously named Zinc Finger Protein 9, ZNF9 gene) [4]. Both DM1
and DM2 are progressive multisystemic disorders characterized by
muscle weakness, myotonia, cataracts, cardiac conduction defects,
cerebral involvement and endocrinological disturbances such as
increased insulin resistance and male hypogonadism. Experimen-
tal evidence supports an RNA gain-of-function mechanism of
expanded transcripts in both DM1 and DM2 in which repeat
containing transcripts from the expanded allele accumulate in
nuclei as foci and alter the functions of RNA binding proteins
involved in regulating alternative splicing and mRNA translation
[5,6]. The alteration of pre-mRNA processing strengthens the
hypothesis of a spliceopathy which leads to inappropriate
expression of embryonic splicing isoforms in adult tissues thus
explaining, at least in part, the multisystemic aspect of the disease
[7]. Expanded CUG/CCUG repeats mediate their effects on
alternative splicing regulation through at least two RNA binding
proteins: muscleblind like 1 (MBNL1) and CUGBP/Elav-like
family member 1 (CELF1/CUGBP1) [8]. MBNL1 preferentially
recognizes CUG or CCUG repeats when they are pathologically
expanded [9,10] and is sequestered by ribonuclear foci in DM1
and DM2 cells [9,11,12] resulting in a loss of MBNL1 activity. In
contrast, CUGBP1 does not colocalize with ribonuclear foci in
DM1 cells [9,13,14], however this protein may have a role in the
pathogenesis of splicing abnormalities because it is overexpressed
in DM1 myoblasts, skeletal muscle and heart tissues [15–17].
Although DM1 and DM2 have similar clinical and genetic
characteristics, they also present a number of very dissimilar
features. DM1 is characterized by the phenomenon of anticipa-
tion, by which the disease has an earlier onset and more severe
course in subsequent generations. Thus the clinical spectrum of
DM1 include four main categories, each presenting specific
clinical features: the congenital form that presents the most severe
phenotype characterized mainly by CNS involvement and mental
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e83777
retardation, the childhood-onset form with school mating and
psychological problems, the adult-onset (‘‘classical’’ DM1) where
the core features are facial weakness with ptosis, myotonia and
distal muscle weakness, and the late-onset or oligosymptomatic
patients where only limited features are found on clinical and
paraclinical assessment. The DM1 mutation length predicts the
clinical outcome to some extent: oligosymptomatic 50–100
repeats, classical DM1 100–1.000 repeats; congenital .1.000
repeats [18,19]. There is a relative correlation between the length
of CTG repeat expansions and age of onset for DM1 patients with
CTG ,400, but correlation between repeat length and disease
severity is poor for long repeats [1,20,21]. In DM2 there are no
distinct clinical subgroups although initially, different phenotypes
of DM2 with proximal muscle weakness were described: DM2/
Proximal Myotonic Myopathy (PROMM) and Proximal Myotonic
Dystrophy (PDM) [22–25]. PDM patients show many features
similar to those found in PROMM, including proximal muscle
weakness, cataracts, and electrophysiologically detectable myoto-
nia. Unlike PROMM patients, however, they do not report
myalgias, symptomatic myotonia, or muscle stiffness. Instead they
present traits not present in PROMM, such as pronounced
dystrophic-atrophic changes in the proximal muscles and late-
onset progressive deafness [24]. The most important discrepancy
between DM1 and DM2 is absence of a congenital form in DM2
[26,27]. In DM2 the smallest reported mutation vary between 55–
75 CCTG [4,28] and the largest expansions have been measured
to be up about 11.000 repeats [4], however the size of CCTG
repeat expansion in leukocyte DNA in DM2 seems to relate in
large part to the age of the patient and not necessarily to the
severity of symptoms or manifestations. Despite the CCUG
expansions are longer than DM1 CUG expansions, DM2 shows
a less severe phenotype. Clinical myotonia is usually milder in
DM2 and histopathological features in DM1 and DM2 are also
different. In DM2 a subpopulation of extremely atrophic type 2
fibers, including the nuclear clump fibers, are present [1,29,30].
Recent studies have indicated that cardinal features of DM1 can
be reproduced in the absence of nuclear inclusions and that RNA
foci formation and splicing defects are separable [31,32].
Moreover, DM1-associated splicing defects have been observed
in mouse models of other muscular dystrophies indicating that
spliceopathy is secondary to muscle damage [33]. However to
date, literature has been focused on reinforcing the prevailing
common model of DM pathogenesis based on the presence of
mutant RNA foci in cell nuclei and spliceopathy. On the other
hand, the existence of disease-specific features that make DM1 and
DM2 clearly separate diseases and the existence of DM1 and DM2
distinct subtypes suggest that other cellular and molecular
pathways are involved besides the shared pathogenetic model
hypothesized. Moreover, the RNA gain of function toxicity has
been better characterized in DM1 than in DM2 probably due to a
greater availability of DM1 samples and mouse models. Impor-
tantly, the role of CUGBP1 in DM2 is particularly intriguing with
contradictory results being reported. Indeed it appears that in
DM1 a combined effect of decreased MBNL1 and increased
CUGBP1 activity lead to misregulated alternative splicing and
other changes of the muscle transcriptome [5,34]. Instead in DM2,
splicing abnormalities are also associated with the sequestration of
MBNL1 protein by expanded transcripts [5,12], however evidence
that CUGBP1 upregulation also occurs in DM2 is conflicting [34–
36]. Timchenko and colleagues reported an increase of CUGBP1
in DM2 cultured myoblasts and muscle biopsies analyzing
cytoplasmic extracts [34]. Moreover they reported that expression
of pure RNA CCUG repeats in normal human myoblasts, in
C2C12 cells and in a DM2 mouse model also increased levels of
CUGBP1 [34]. On the contrary, in two different reports, the
analysis of total cellular extract from DM2 cultured myoblasts and
from muscle biopsies of DM2 patients did not show differences in
CUGBP1 levels [35,36]. Nevertheless, it should be noted that in
these works no mention is made of either the number or the
clinical features and muscle histopathology of the patients used. In
DM2 patients the role of ZNF9/CNBP expression is still
controversial and requires additional investigation since some
DM2 patients show reduced protein levels but others do not
[36,37–40]. In this study we have analysed the histopathological,
biochemical and molecular features of skeletal muscle biopsies
from DM1 and DM2 patients in relation to presenting phenotypes
(mild-E1 vs. classic-E2 vs. CDM in DM1 and PROMM vs. PDM
vs. paucisymptomatic in DM2). This is the first study where the
expression of CUGBP1 protein has been examined in a large
cohort of DM2 patients. Moreover, DM2 muscle biopsies have
been characterized together with several DM1 and control
samples. This work intends to clarify which factors may act as
modifiers of disease-specific manifestations in DM beyond
spliceopathy.
Materials and Methods
Patients and skeletal muscle samples
This study was authorized by the Institutional Ethics Commit-
tee (ASL MI2-Melegnano via VIII Giugno, Milan) and was
conducted according to the principles expressed in the Declaration
of Helsinki, the institutional regulation and Italian laws and
guidelines. All blood samples and muscle biopsies were used for
this study after receiving written informed consent from the
patients. With regard to children participants, we have obtained
written informed consent from their parents.
Human muscle biopsies from biceps brachii muscle were taken
under sterile conditions from 18 DM1, 20 DM2 patients and from
8 age-matched subjects who underwent muscle biopsy and
resulted negative. Muscle samples were trimmed of blood vessels,
fat and connective tissues and then fresh-frozen in isopentane
cooled in liquid nitrogen. The diagnosis of DM was based upon
the clinical diagnostic criteria set by the International Consortium
for Myotonic Dystrophy [41]. Fluorescence in situ hybridization
was performed on DM2 muscle frozen sections using a (CAGG)5
probe as previously reported by Cardani et al. [42] to verify the
presence of ribonuclear inclusions.
Genetic analysis of CTG and CCTG expansions
For DM1 genotyping, 1 mg of genomic DNA of each patients
extracted from peripheral blood leukocytes were by ‘‘Myotonic
Dystrophy SB kit’’ (Experteam s.r.l, Venezia, Italy). Forward primer
was labelled at the 5’ end with fluorescent tag 6-FAM. PCR
conditions were: one cycle of 1 min at 94uC; 28 cycles of 20 sec at
94uC and 7 min at 62uC; and finally 10 min at 72uC. The
amplifications were performed by MyCycler instrument (BioRad).
After the amplification 20 ml of each PCR products were run on
3.5% MetaPhore agarose gel at 100V and stained with ethidium
bromide. Alleles with less than 100 repeats were analyzed by
capillary electrophoresis on 3500 Genetic Analyzer (Applied
Biosystems) using LIZ600 as size standard. The analysis of results
was performed using GeneMapper v4.1 (Applied Biosystems). For
alleles with more than 100 repeats Southern blot hybridization was
performed using a non-radioactive Digoxigenin-based probe
5’DIG- labelled [CTG]10, and the [CTG] repeats size was
determined comparing the bands pattern obtained by Southern
Blot Analysis with two DNA Molecular Weight Markers VII and
VIII, DIG-labelled (Roche Diagnostics). DM2 genotyping has
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been performed on genomic DNA extracted from peripheral
blood leukocytes by long-PCR analysis as described [37,43].
Muscle histopathology
Muscle tissue was fresh-frozen in isopentane cooled in liquid
nitrogen. Histopathological analysis was performed on serial
sections (8 mm) processed for routine histological or histochemical
stainings. A standard myofibrillar ATPase staining protocol was
used after preincubation at pH 4.3, 4.6, and 10.4 [44]. The most
typical alterations, such as nuclear clump fibers (i.e. aggregates of
myonuclei with a thin rim of cytoplasm), nuclear centralization
and fiber size variability were evaluated on serial muscle sections.
Immunohistochemistry
Serial transverse muscle cryostat sections 6 mm thick were cut
for immunohistochemical staining (IHC). Sections were air-dried
and rehydrated in phosphate buffer pH 7.4 (PBS). Non-specific
binding sites were blocked with normal goat serum (NGS; DAKO)
at a dilution 1:20 in PBS containing 2% bovine serum albumin
(BSA; Sigma-Aldrich) for 20 min at room temperature (RT).
Mouse monoclonal primary antibodies against two different
myosin heavy chain (MHC) isotypes were used at the following
dilutions: MHCfast, 1:400 in PBS+2% BSA (Sigma-Aldrich);
MHCslow, 1:400 in PBS+2% BSA (Sigma-Aldrich). Each
antibody was applied for 1 h at RT. After washing in PBS 3
times for 5 min, sections were incubated with goat anti-mouse
biotinylated secondary antibody diluted 1:300 in PBS+2% BSA for
1 h at RT. After PBS washing, sections were incubated with
StreptABComplex (DAKO) for 30 min and then exposed to the
3,3’-diaminobenzidine tetrahydrochloride (DAB) chromogen re-
action solution for 10 min. Nuclei were counterstained with
Mayer’s hematoxylin. Quantitative evaluation of fiber diameter
was made as described previously by Vihola et al. [29] on images
taken with a slide scanner ScanScope CS (Aperio Technologies,
Vista, CA, USA) using the slide scanner software ImageScope.
The size of muscle fibers was assessed by measuring the ‘‘smallest
fiber diameter.’’ All data were elaborated using Microcal Origin
(Microcal Software Inc., Northampton, MA, USA).
Western blot analysis
Whole cell extracts were obtained from fifteen-twenty consec-
utive muscle cryostat sections 10 mm thick homogenized in 60 ml
of 50 mM TrisHCl with 5% SDS (pH 7.5). After incubating on ice
for 15 min, samples were centrifuged at 5,700 g for 12 min at 4uC,
and supernatant was collected and stored at 280uC. Pellets were
resuspended in 50 mM TrisHCl with 5% SDS (pH 7.5) and stored
at 280uC. Protein concentration in each sample was determined
by using BCA Protein Assay (Bio-Rad Laboratories). An equal
amount of protein was loaded per lane and electrophoresed on
12% sodium dodecyl sulfate–polyacrylamide gels, and then
transferred to nitrocellulose Protran membranes (Schleicher &
Shuell GmbH). After blocking non specific sites in TrisHCl buffer
pH 7.5 (TBS) containing 5% BSA for 30 min at 42uC, membranes
were incubated overnight at 4uC with rabbit polyclonal anti-
CUGBP1-posphoS28 (Abnova; 0.5 mg/ml), with mouse monoclo-
nal anti CUGBP1 (Santa Cruz; clone 3B; 1:1000), or with rabbit
polyclonal anti-ZNF9/CNBP (1:1000) [45]. After several washes
in TBS+0.2% Tween20 or TBS+0.3% Tween20, membranes
were incubated with horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit secondary antibodies (Jackson ImmunoR-
esearch Laboratories) diluted 1:5000 or 1:10000 in TBS+5%
BSA+ 0.2% Tween20 respectively. Membranes were washed and
immune complexes were detected using the ECL detection system
(Amersham Pharmacia Biotech, Piscataway, NJ). GAPDH (poly-
clonal antibody diluted 1:80000; Sigma–Aldrich) was used as
internal control to verify and correct for loading error. Blots have
been performed in triplicate.
Two-dimensional gel electrophoresis (2D-GE)
6 DM1 (3 DM1-E1, 3 DM1-E2), 6 DM2 (3 DM2-PDM, 3
DM2-PROMM) and 6 control samples have been analysed. Each
sample containing 50 mg proteins was resuspended in a solution
containing 7 M urea, 2 M thiourea, and 4% 3-((3-cholamidopro-
pyl)-dimethylammonio)-1-propanesulfonate (CHAPS). Samples
were used to rehydrate immobilized pH gradient (IPG) strips just
before isoelectrofocusing. For the first-dimension electrophoresis,
samples were applied to IPG strips (11 cm, pH 3–10 linear gradient;
GE Healthcare). Strips were rehydrated at 20uC for 1 h without
current and for 12 h at 30 V in a buffer containing 7 M urea, 2 M
thiourea, 4% CHAPS, 1 mM dithiothreitol (DTT), and 1% IPG
buffer 3–10 (GE Healthcare). Strips were focused at 20uC for a total
of 70,000 V/h at a maximum of 8000 V using the Ettan IPGphor II
system (GE Healthcare). The focused IPG strips were stored at
280uC. For the second dimension, IPG strips were equilibrated at
room temperature for 15 min in a solution containing 6 M urea, 2%
SDS, 30% glycerol, 50 mM Tris–HCl (pH 8.8), and 10 mg/ml
DTT and then reequilibrated for 15 min in the same buffer
containing 25 mg/ml iodoacetamide in place of DTT. The IPG
strips were placed on top of a 12% polyacrylamide gel and proteins
were separated at 25uC with a prerun step at 20 mA/gel for 1 h and
a run step at 30 W/gel for 3.5 h. After run, gels were transferred to
nitrocellulose Protran membranes (Schleicher & Shuell GmbH).
CUGBP1 and GAPDH, used to normalize protein load on IPG
strip, have been immunodetected as described above.
Study of alternative splicing
Frozen muscle samples were practiced for the extraction of total
RNA using TRIzol reagent (Gibco BRL, Gaithersburg, MD) and
1 mg of RNA was reverse transcribed according to the cDNA
protocol of the High Capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA). Splicing pattern profile of the IR,
CLCN1, MBNL1, SERCA1 and CAPZB genes was carried out as
described [46–48]. Total PCR products, obtained within the linear
range of amplification, were electrophoresed on 2.5% agarose gel.
Quantitative analysis of the amplified products was performed using
SybrGreenII-stained gels (Perkin-Elmer Life Science, Massachu-
setts, USA) scanned on a fluorimager 595 (Amersham Biosciences,
Buckinghamshire, UK). The intensity of each band and the fraction
of abnormally (or pathologically) spliced (AS) isoforms (AS-
isoforms/total) were quantified by densitometry using ImageQuant
software. Statistical methods were used to analyze the differences in
the identified splice variants between DM1 and DM2 patients
respect to controls. Control of the RT-PCR reaction was based on
the expression level of the glucose phosphate isomerase housekeep-
ing gene (GPI) and all amplifications have been carried out in
triplicate using independent cDNA samples.
QRT-PCR expression analysis of the CLCN1, ZNF9/CNBP
and CUGBP1 genes
Following RNA extraction and retro-transcription, cDNA of
DM samples were also used to quantify the expression level of the
CLCN1, ZNF9/CNBP and CUGBP1 genes. The total expression of
mentioned genes was evaluated using specific TaqMan gene
expression assays: CLCN1 [Hs00163961_m1], ZNF9/CNBP
[Hs00231535_m1] and CUGBP1 [Hs00198069_m1] (Applied
Biosystems). The VIC-labelled b2-microglobulin gene (B2M:
GenBank accession #NM_004048) was used as housekeeping
Overexpression of CUGBP1 in DM1 Muscle
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e83777
internal control gene, as described [49]. The simultaneous
measurement of genes-FAM/B2M-VIC expression allows to
normalize the amount of cDNA added per sample. Each PCR
reaction was performed in triplicate using the TaqMan Universal
PCR Master Mix and the ABI PRISM 7500 Fast System (Applied
Biosystems). A comparative threshold cycle (Ct) was used to
determine CLCN1 and ZNF9/CNBP genes expression compared
to a calibrator (median value of control subjects). Hence, steady-
state mRNA levels were expressed a n-fold difference relative to the
calibrator. For each sample, genes’ Ct value was normalized using
the formula DCt = Ct genes – Ct B2M. To determine relative
expression levels, the following formula was used: DDCt = DCt
sample 2 DCt calibrator. The value adopted to plot relative gene
expression was calculated using the expression 22DDCt. The relative
quantification of the CUGBP1 mRNA steady-state level was
calculated using the Pfaffl equation accordingly to Pfaffl et al [50].
Statistical analysis
Overall statistical significance has been calculated by using the
Kruskal-Wallis test (non parametric ANOVA) and significant
differences between groups have been determined using the
Dunn’s multiple comparisons post-test.
Results
Patients
On the basis of clinical phenotype, DM1 cohort has been
divided in three subphenotypes: 5 DM1 patients with mild
phenotype (E1), 10 DM1 patients with classic phenotype (E2) and
3 DM1 adult patients with Congenital Myotonic Dystrophy
phenotype (CDM). The DM2 cohort included: 5 DM2 patients
with a paucisymptomatic (PS) phenotype, 5 DM2 patients with
Proximal Myotonic Dystrophy (PDM) phenotype (severe atrophy
and myotonia only at EMG) and 10 DM2 patients with Proximal
Myotonic Myopathy (PROMM) phenotype (proximal muscle
weakness and myotonia). Data on DM patients used in this study
are reported in Table 1.
Muscle histopathology
Analysis of muscle sections immunostained for MHC fast and
slow myosin allows us to detect and measure fibers smaller than
5 mm, including all nuclear clump fibers which are recognizable by
the presence of a thin rim of immunoreaction around the nuclei.
The metahistograms based on the analysis of fiber diameters on
immunostained muscle sections and the evaluation of atrophy (AF)
and hypertrophy (HF) factors are reported in Figure 1. An increase
of both type 1 and type 2 fiber AF is present in DM1-E2 and
DM1–CDM (Figs. 1B, C). The AF increase is not present in DM1-
E1 (Fig. 1A). Type 2 fiber atrophy is most evident in DM1-E2
which shows a bimodal size distribution histogram of type 2 fibers
(Fig. 1B). Among DM2 muscles, DM2-PDM and DM2-PROMM
show an increase of both AF and HF not evident in DM2-PS (Figs.
1D-F). In DM2-PROMM muscles, atrophy affects type 2 but not
type 1 fibers whereas in DM2-PDM a slight increase of type 1 fiber
AF is also present (Figs. 1E, F). Both DM2-PDM and DM2-
PROMM exhibit a bimodal size distribution histogram of type 2
fibers. The most severe histopathological alterations are present in
muscles from patients presenting the most severe clinical
phenotype i.e. DM1-E2, DM1-CDM, DM2-PDM and DM2-
PROMM. In DM1-E2 and DM1-CDM, nuclear clumps fibers
and highly atrophic fibers express MHC fast myosin and a
coexpression with MHC slow myosin is evident in most of them
(Figs. 2C, D). In DM2-PDM and DM2-PROMM muscles,
numerous nuclear clumps fibers expressing only MHC fast myosin
Table 1. Clinical data on DM patients used in this study.
Phenotype Clinical features Age at biopsy MRCa Diabetes
EKGb Abnormalities
%
tot %
Controls Healthy subjects No clinical signs 45.2613.8 149.361.0 0% 0%
(n = 8)
DM1 (n=18) Mild (n = 5) Minimal clinical signs 41.2617.5 149.661.7 0% 0%
(E1: 50,CTG,150) (MIRSc = 2)
Classic (n = 10) Overt clinical symptoms 44.3610.5 118.9619.3 0% 60%
(E2: 150,CTG,1000) (MIRS = 3-4)
Congenital Myotonic
Dystrophy (n = 3)
Symptoms at birth 22.7610.7 114.764.2 0% 100%
(CDM: CTG.1000)
DM2 (n=20) Paucisymptomatic (n = 5) Absence of muscular
weakness
38.0613.4 149.661.0 0% 0%
(PS)
Proximal myotonic dystrophy
(n = 5)
Severe atrophy 65.068.4 131.4611.4 40% 0%
(PDM) No clinical myotonia
Proximal myotonic myopathy
(n = 10)
Proximal muscle weakness 55.066.1 142.662.5 20% 20%
(PROMM) Myotonia
aMedical Research Council, scale for muscle strength; scale (0–5 grade) on 15 muscles at both sides in the upper and lower limbs for a total of 150 maximum score.
bElectrocardiogram, included first-degree atrio-ventricular block, incomplete or complete bundle-branch block.
cMuscle Impairment Rating Scale, stage of the disease for DM1 patients [73].
doi:10.1371/journal.pone.0083777.t001
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are present (Figs. 2F, G). Central nucleation is always present and
involved prevalently type 1 fibers in DM1 muscles and type 2
fibers in DM2 muscles. As in control muscles, no histopathological
changes are instead observed in muscles from both DM1-E1 and
DM2-PS where no nuclear clumps fibers or central nuclei are
present (Figs. 2A, B, E).
CUGBP1 protein expression is more elevated in DM1
than in DM2 skeletal muscle
In order to resolve the controversial results on CUGBP1 protein
expression in DM2 muscle, we have examined the protein levels of
CUGBP1 in biceps brachii muscle samples from DM1, DM2 and
control individuals by western blotting analysis (Fig. 3A). An
increase of CUGBP1 protein level is present in DM muscles as
compared to controls even if not statistically significant due to the
high interindividual variability observed in all groups. However,
the increase of protein expression appears to be higher in DM1
than in DM2 (Fig. 3B). When considering the 3 DM1 different
phenotypes separately, the increase is evident only in DM1-E2
while in DM1-CDM and DM1-E1 muscles the protein levels
appear to be equal to those observed in control muscles (Figs. 3C).
A clear correlation between the AFs and the CUGBP1 expression
levels has been observed in DM1 muscles (p,0.01, data not
Figure 1. Metahistograms have been obtained from the analysis of muscle fiber diameters in DM1 patients (A-C) and in DM2
patients (D-F). The results are based on sections immunostained for MHC fast or slow myosin. Tables show the relative atrophy or hypertrophy
factors in each subphenotype considered. Data relative to each DM1 and DM2 phenotypic groups have been obtained by pooling the findings of
each patient: DM1-E1 (n = 3), DM1-E2 (n = 5), DM1-CDM (n= 3), DM2-PS (n = 4), DM2-PDM (n= 5) and DM2-PROMM (n= 5).
doi:10.1371/journal.pone.0083777.g001
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shown). A slight increase in CUGBP1 protein expression is
observable in DM2 muscles compared to controls and this increase
is present in DM2-PDM and DM2-PROMM phenotypes but not
in DM2-PS. However the CUGBP1 levels in DM2-PDM and
DM2-PROMM muscles appear to be lower than those observed
in DM1-E2 (fold increase 1.3 vs 1.6 compared to controls) (Fig.
3C). Nevertheless, it has been reported that the increase of
CUGBP1 steady state protein level in DM1 cultured cells or
animal models is related to protein hyperphosphorylation [51].
Several kinases phosphorylate CUGBP1 at different residues and
multiple functions of the protein are regulated by phosphorylation
at distinct sites. While the specific sites of phosphorylation by PKC
have not yet been identified, it has been demonstrated that Akt
phosphorylates CUGBP1 at serine-28 (S28) and cyclin D3/cdk4 at
serine 302 (S-302) [39,51,52]. Since it has been reported that
activation of Akt pathway increases CUGBP1 phosphorylation at
S-28 in DM1 myoblasts and skeletal muscle, we tested if the
increase of CUGBP1 expression observed in our DM cohort is
related to an increase of CUGBP1 phosphorylation at S-28.
Phosphorylation at S-28 controls nucleus-cytoplasm distribution of
CUGBP1, thus it appears that an increase of the expression of
CUGBP1-p-S28 isoform may affects CUGBP1 homeostasis since
CUGBP1 regulates splicing in the nucleus and stability and
translation of mRNA in the cytoplasm, Among all the DM muscles
analysed, an increase of CUGBP1-p-S28 was observed only in
DM1-E2 which also showed the higher level of CUGBP1
expression. In all other groups, CUGBP1-p-S28 levels are similar
to those observed in controls (Fig. 3C). We additionally analysed
DM muscle samples through 2D-GE in order to evaluate the
CUGBP1 phosphorylation pattern and thus investigate in human
biopsies the reported striking protein shift toward a more acidic
position previously described in cell system. We analysed
CUGBP1 phosphorylation pattern in 12 DM muscle samples
confirming an overexpression of CUGBP1 protein only in DM1-
E2 respect to control and DM2 biopsies (Fig 3D). In particular,
CUGBP1 showed a typical 3 spots pattern in the majority of the
sample tested, whereas an additional more acid spot appears only
in DM1-E2 sample (Fig. 3D). The appearance of this left spot
confirms an increase of the expression of CUGBP1-p form in
DM1-E2 patients. Moreover, this additional spot suggests the
presence of a more phosphorylated CUGBP1 isoform in DM1-E2,
however increased abundance of this isoform should be justified by
the overexpression of CUGBP1 in DM1-E2. In order to
understand whether CUGBP1 phosphorylation pattern is also
altered in DM2 muscles we have compared similar signals of 2D
patterns among controls, DM1-E2 and DM2-PROMM to
evaluate abundance of different phosphorylation isoforms. As
shown in Figure 3E, the CUGBP1 phosphorylation pattern does
not show significant alteration in protein spot relative abundance
and it does not highlight a hyperphosphorylation of the protein
suggesting a similar phosphorylation pattern among the DM
phenotype investigated.
CUGBP1 transcript level was higher in both DM1 and DM2
compared to controls however differences were not statistically
significant (Fig 3F).
ZNF9/CNBP expression is reduced in DM2 muscle
biopsies
We have analysed the expression of ZNF9/CNBP at protein
and mRNA levels to verify if there is a relationship between their
expression and the DM2 clinical severity. ZNF9/CNBP protein
levels in examined DM2 muscles are significantly reduced
compared with DM1 and control samples whereas the protein
level is similar among DM2 subphenotypes (Fig. 4 A-C). Also
ZNF9/CNBP mRNA expression appears to be lower in DM2
muscle biopsies than in control biopsies (p,0,05; data not shown)
and, in agreement with data on protein expression, mRNA levels
are similar in the DM2 subtypes considered (Fig. 4D).
IR, CLCN1, SERCA1, MBNL1 and CAPZB alternative
splicing alterations are related to clinical severity of DM
subphenotypes
In this work we have analysed splicing isoforms of IR, CLCN1,
SERCA1, MBNL1and CAPBZ genes in muscle biopsy from DM
patients to understand if a relationship may exist between the
degree of splicing alteration and the phenotype severity. Exons
inclusion for all these genes is developmentally regulated and
Figure 2. Fast myosin immunostaining of skeletal muscle
transversal sections obtained from a healthy patient (A),
DM1 patients (B-D) and DM2 patients (E-G). Type 2 fibers (fast
positive fibers) are stained in brown. Muscle from DM1-E1 (B) and DM2-
PS (E) patients show a normal histological muscle pattern similar to
those observed in control muscle section (A). Muscle from DM1-E2 (C)
and DM1-CDM (D) patients show a high fiber size variability with both
type 1 (unstained fibers; white arrows) and type 2 (black arrows)
atrophic fibers, fast positive nuclear clumps (arrowheads) and a
preferential type 1 fiber central nucleation (asterisks). Muscle from
DM2-PDM and DM2-PROMM patients also show high fiber size
variability with very small type 2 fibers (black arrows), type 2 nuclear
clumps (arrowheads) and a preferential type 2 fiber central nucleation
(asterisks).
doi:10.1371/journal.pone.0083777.g002
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dependent on MBNL1 (SERCA1 and MBNL1 genes) [53,54],
CUGBP1 (CAPZB gene) [53] or both MBNL1/CUGBP1 proteins
(CLCN1 and IR genes) [55–57]. We have identified similar defects
in IR, CLCN1, SERCA1, MBNL1 and CAPZB splicing in DM1 and
DM2 where the frequency of abnormal isoforms are significantly
increased as compared to controls (Fig. 5A-C). The mean
percentage of IR-A isoform (IR–A/IR–A+IR–B ratio) in DM1
and in DM2 was 64% and 65% respectively, whereas in controls
was 27%. This could explain the insulin resistance in both forms of
the disorder. The expression pattern of the CLCN1 gene has been
analyzed across exon 7a, which is abnormally included in DM
muscles. In DM1 and DM2 in fact we found 30% and 36% rate of
exon 7a inclusion compared to 7% in the control group. SERCA1
gene is developmentally regulated and SERCA1b isoform, not
including exon 22, is characteristic of dystrophic muscle and
myotubes [46]. Accordingly to this observation, our DM1 and
DM2 samples showed higher level of SERCA1b isoforms than the
controls (median percentage of 36% and 22% vs. 4% in controls).
Similarly, RT-PCR analysis of MBNL1 splicing pattern across
exon 7 region indicated that the ratio of MBNL1 exon 7 inclusion
on total MBNL1 (MBNLex7/MBNLex7+MBNL1D7) is 52% in
DM1, 59% DM2 and 33% in control samples. On the basis of the
observed CUGBP1 increased protein levels in DM1 muscle, we
also analyzed the expression of the CAPZB gene, which encodes
for the F actin capping protein beta subunit. CAPZB splicing is
dependent only on CUGBP1 and is misregulated in DM1 patients
[48,54]. RT-PCR analysis showed that the ratio of fetal CAPZB
exon 8-excluding isoform on total CAPZB transcripts (CAPZBD8/
CAPZBEx8+CAPZBD8) is 48% in DM1, 37% DM2 and 18% in
control groups. Interestingly, the DM1-E2 was the category with
the highest levels of CAPZB Ex8-exclusion transcripts (59%). When
considering single phenotypes, DM1-E1 muscles show a lower
frequency of abnormal isoforms than those observed in DM1-
CDM and DM1-E2 (Fig. 5D). Also in DM2 group, the degree of
expression of pathological isoforms in the paucisymptomatic
phenotype appears to be lower than those observed in DM2-
PDM and DM2–PROMM (Fig. 5E).
It has been shown that the increase of CUGBP1 contributes to
the IR and CLCN1 splicing alteration and is the only factor
regulating exon inclusion of the CAPZB gene [53,58]. We have
found a significant correlation between CUGBP1 protein expres-
sion in DM muscles and the frequency of IR, CLCN1 and CAPZB
Figure 3. CUGBP1 expression in biceps brachii muscle samples
from healthy, DM1 and DM2 patients. A-E. Analysis of CUGBP1
protein expression by western blot. A. Representative western blot
analysis of CUGBP1 and CUGBP1-p-S28 protein expression in healthy,
DM1 and DM2 patients. Density of the bands has been normalized with
GAPDH expression used as internal control. B. Histograms represents
mean values of CUGBP1 protein expression analysed by densitometry in
DM1 (n = 18) and DM2 (n= 20) patients compared to controls (n = 8).
Bars represent standard error of the mean (SEM). An increase of CUGBP1
and CUGBP1-p-S28 expression is more evident in DM1 muscles. C.
CUGBP1 expression has been also evaluated in DM1 and DM2
phenotypic subgroups (DM1-E1 (n = 5), DM1-E2 (n = 10), DM1-CDM
(n= 3), DM2-PS (n = 5), DM2-PDM (n= 5) and DM2-PROMM (n= 10))
compared to controls (CTR; n = 8). Bars represent SEM. Among all DM
muscles analysed, the increase of CUGBP1 and CUGBP1-p-S28 levels is
more evident in DM1-E2. D. Representative CUGBP1 protein expression
pattern of 50 mg of biceps brachii muscle samples from healthy, DM1-
E2 and DM2-PROMM patients determined by western blot analysis after
2D-GE separation (left panel). In order to evaluate protein load, GAPDH
has been also detected in the 2D map (right panel). E. Since CUGBP1 is
overexpressed in DM1-E2 (see Figure 3D), different exposition times (2
hours for DM2 and controls vs 5 minutes for DM1) have been compared
to obtain similar western blot signals with the intent to compare the
CUGBP1 phosphorylation patterns (protein distribution among the
different CUGBP1 phosphorylated isoforms) in DM1, DM2 and control
samples. As illustrated in the left panel, CUGBP1 phosphorylation
pattern is not altered in DM1 and DM2 muscles as compared to
controls. F. CUGBP1 mRNA expression in biceps brachii muscle samples
from DM1 (n = 11), DM2 (n = 14) and controls (CTR, n = 4) patients. Bars
represent standard deviation.
doi:10.1371/journal.pone.0083777.g003
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pathological isoforms. A significant correlation is also evident in
DM1 cohort but not in DM2 cohort. The increase of CUGBP1
expression significantly correlate with the splicing alterations
observed for SERCA1 and MBNL1 although CUGBP1 does not
seem to be directly involved in splicing misregulation of these
genes.
No correlation has been found between the age of patients and
the degree of splicing deregulation of the genes examined both in
DM1 and DM2 except for IR gene in DM2 cohort (p,0,01; data
not shown).
Since an elevated concentration of intracellular Ca2+ has been
suggested to be a possible cause of muscle degeneration [59], we
have analysed if there is a correlation between observed
histopathological alterations in DM muscles and the expression
of pathological isoform of SERCA1 which is one of the main
regulators of intracellular Ca2+ homeostasis in skeletal muscle cells.
We have found a significant correlation between SERCA1 splicing
alteration and the atrophy factor in DM1 but not in DM2 muscle.
A significant correlation between SERCA1 splicing alteration and
hypertrophy factor has been found in DM2.
CLCN1 mRNA expression levels are similar in DM2
subgroups
CLCN1 mRNA expression levels in DM2 muscle biopsies is
reduced as compared to control biopsies (p,0,01, data not shown)
and the mRNA levels appear to be significantly lower in DM2-
PDM than in controls (Fig. 6). Statistical analysis does not reveal
differences in CLCN1 mRNA expression levels between DM2
phenotypic subgroups considered in this work (Fig. 6). This feature
is confirmed also by splicing analysis with densitometry software
where DM2-PS, DM2-PDM and DM2-PROMM present about
the same level of pathological isoforms.
Discussion
Myotonic dystrophies are autosomal dominant diseases which
share many phenotypic features, however these two disorders also
present a number of very dissimilar features making them clearly
separate diseases. It is important to underline that DM1 and DM2
phenotypes present a wide clinical spectrum that includes different
clinical subphenotypes indicating that molecular pathomechanism
of DM is more complex than that actually suggested. The results of
our study carried out on skeletal muscle from different DM1 and
DM2 subphenotypes seem indicate that the splicing and muscle
pathological alterations observed are related to the clinical
phenotype. Muscle histopathology of most of DM1 and DM2
patients examined in this work showed the characteristic
myopathic features of these diseases. Moreover, in DM2 muscles
the mainly affected fiber type is type 2 fibers as previously reported
by other authors [29,60,61]. However this is true for DM1 and
DM2 patient groups showing the more severe multisystemic
phenotypes but not for the groups of paucisymptomatic patients,
i.e. DM1-E1 and DM2-PS, who present none or minimal muscle
histopathological alterations. Moreover as expected, alteration of
alternative splicing of IR, CLCN1, MBNL1, SERCA1 and CAPZB
genes is evident in both DM1 and DM2 muscle biopsies despite
the clinical phenotype. However it appears that DM1-E1 and
DM2-PS patients, who show the less severe clinical and muscle
histopathological phenotype, also present a milder spliceopathy
profile than those observed in the other DM patients analyzed. It
Figure 4. ZNF9/CNBP expression in biceps brachii muscle
samples from healthy, DM1 and DM2 patients. A-C. ZNF9/CNBP
protein expression determined by western blot analysis. A. Represen-
tative western blot analysis of ZNF9/CNBP protein expression in healthy,
DM1 and DM2 patients. Density of the bands has been normalized with
GAPDH expression used as internal control. B. Histograms represents
mean values of ZNF9/CNBP protein expression analysed by densitom-
etry in DM1 (n= 11) and DM2 (n= 14) patients compared to controls
(n = 8). ZNF9/CNBP levels are significantly lower in DM2 muscles as
compared to DM1 and control muscles. *p,0.05; **p,0.01. C. ZNF9/
CNBP expression has been also evaluated in DM1 and DM2 phenotypic
subgroups (DM1-E1 (n = 3), DM1-E2 (n = 5), DM1-CDM (n= 3), DM2-PS
(n = 4), DM2-PDM (n= 5) and DM2-PROMM (n=5)) compared to controls
(CTR; n = 8). The expressions levels of the protein are similar in the three
DM2 subphenotypes considered. D. ZNF9/CNBP mRNA expression
in biceps brachii muscle samples from DM2 patients (DM2-PS (n = 4),
DM2-PDM (n= 5) and DM2-PROMM (n= 5)) and controls (CTR, n = 3).
mRNA levels are similar in DM2 subgroups. Bars represent SEM.
doi:10.1371/journal.pone.0083777.g004
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should be noted that the degrees of CLCN1 splicing misregulation
in DM2-PDM is similar to that observed in DM2-PROMM
despite myotonia in DM2-PDM is not evident at clinical level.
Also, the CLCN1 mRNA expression levels appear to be similar in
DM2-PDM and DM2-PROMM. However it is possible that
symptomatic myotonia is not detectable in DM2-PDM patients
due to the high degree of atrophy factor observed in skeletal
muscle. It is well known that in DM the clinical myotonia is not
present at elevated degree of dystrophy or atrophy. Since an
elevated concentration of intracellular Ca2+ has been suggested to
be a possible cause of muscle degeneration [59], we have analysed
if there is a correlation between histopathological alterations
observed in DM muscles and the expression of pathological
isoform of SERCA1 which is one of the main regulators of
intracellular Ca2+ homeostasis in skeletal muscle cells. Both in
DM1 and DM2 we have found a positive correlation between the
muscle alterations and the SERCA1 splicing alteration thus
strengthen the hypothesis that aberrant splicing of this transcript
might contribute to severe histopathological alterations in DM
patients.
To better define the molecular pathways which may be involved
in disease-specific manifestations, we have analysed the role of
CUGBP1 particularly intriguing in DM2 since contradictory
results have been reported [34–36]. While it is clear that MBNL1
is depleted from nucleoplasm through recruitment into ribo-
nuclear inclusions both in DM1 and DM2 even when clinical
symptoms and muscle alterations are very mild [35,62–65],
CUGBP1 overexpression has been clearly demonstrated in DM1
but not in DM2 muscle biopsies. Our western blotting analysis of
CUGBP1 protein expression confirms that CUGBP1 is overex-
pressed in DM1 muscle biopsies however the increase is evident
only in DM1-E2 while CUGBP1 protein levels in DM-E1 and
Figure 5. Analysis of alternative splicing of the IR, CLCN1, SERCA1, MBNL1 and CAPZB genes. A, B. Splicing products obtained by RT-PCR
amplification of RNA isolated from biceps brachii muscle samples from DM1 (A), DM2 (B) and control patients. C-E. Densitometric analysis measuring
the fraction of aberrant gene isoforms in DM muscles (C), and in DM1 (D; DM1-E1 (n = 3), DM1-E2 (n = 5), DM1-CDM (n= 3)) and DM2 (E; DM2-PS
(n = 4), DM2-PDM (n= 5), DM2-PROMM (n=5)) phenotypic subgroups compared to controls (CTR). Bars represent SEM; *p,0.05; **p,0.01;
***p,0.001. Alternative splicing of all five genes analysed appear to be altered in DM as compared to non-DM muscles.
doi:10.1371/journal.pone.0083777.g005
Figure 6. Results of QRT-PCR experiments to quantify the
expression level of the CLCN1 mRNA in biceps brachii muscle
samples from DM2 patients (DM2-PS (n=4), DM2-PDM (n=5)
and DM2-PROMM (n=5)) and controls. Each experiment has been
performed in triplicate and the relative amount of the CLCN1 transcripts
has been determined using the b2-microglobulin as endogenous
control gene. Bars represent standard deviation.
doi:10.1371/journal.pone.0083777.g006
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DM1–CDM appear to be similar to those observed in healthy
controls. Moreover CUGBP1 overexpression in DM1-E2 biopsies
is accompanied by a parallel increase of the amount of
phosphorylated isoform. These data correlate with the splicing
analysis of the CAPZB gene which is regulated specifically by the
CUGBP1 protein.
Except for E1-CDM, our data are in line with those reported by
Timchenko et al. [66] on DM1 muscle biopsies. In this work,
CUGBP1 appear to be overexpressed in CDM and E2 patients
but not in E1 patients. However, only one CDM was examined
and no mention was made about the age of the patient.
It has been suggested that in DM1 CUGBP1 may be
responsible for muscle wasting since the transgenic mice with
skeletal muscle-specific expression of CUGBP1 reproduces the
dystrophic muscle histology characteristic of DM1 [67] while
MBNL1 knockout mice do not exhibit severe muscle wasting
suggesting that MBNL1 depletion alone is not able to reproduce
this disease feature [68]. In our work we have found a clear
correlation between CUGBP1 expression and the atrophy factors
found in DM1 muscles. However when considering the different
DM1 clinical phenotypes, DM1-E2 and DM1-CDM show the
higher values of atrophy factor and the most severe muscle
histopathological alterations nevertheless CUGBP1 is overex-
pressed only in DM1-E2 muscles. It should be noted that the
extreme muscle weakness observed in the congenital form of DM1
is not caused by degenerative changes but by developmental
defects. Analysis of muscles from CDM patients has shown that
muscle fibers are immature in foetuses and that the skeletal muscle
maturation is impaired in children [69,70]. However, the analysis
of two successive muscle biopsies of CDM patients showed that in
time the muscle is able to gain a certain degree of maturity but
never becomes normal since it retains discrepancies in fiber size
and the degenerative muscle process begins starting from the
second decade when the morphological alterations become
identical to those described in late onset myotonic dystrophy
[71]. Since we have analysed adult-young CDM patients where
muscle histopathological alterations might be due more to the
developmental defects than to the degenerative process, it is
possible that CUGBP1 expression in our DM1-CDM muscles
appears to be similar to DM1-E1 more than to DM1-E2.
Contrary to DM1, in DM2 muscle biopsies examined in this
work a slight increase of the CUGBP1 protein levels is observed in
DM2-PDM and DM2-PROMM but not in DM2-PS However
this increase is not related to an increase of protein phosphory-
lation. In addition our data on DM2 muscle seem suggest that
perturbation of CUGBP1 amount are not required to produce
histopathological or splicing regulation defects in DM2. We have
observed that the greater expansion in DM2 leads to ribonuclear
foci greater than in DM1 which can sequester larger amount of
MBNL1. Therefore, the depletion of MBNL1 from nucleoplasm
appears to be more extensive in DM2 than in DM1 despite DM1
shows a greater severity of the muscle degeneration (unpublished
data). Thus, since sequestration of MBNL1 evidently has a central
role in splicing misregulation in both types of DM, it appears likely
that in DM1 CUGBP1 overexpression might be an additional
pathogenic mechanism not shared by DM2.
It is relevant to highlight that we do not find differences in
phosphorylation pattern between the DM phenotypes suggesting
that CUGBP1 does not result hyperphosphorylated in DM
compared to control muscles. The discrepancy observed between
our data on CUGBP1 expression/phosphorylation in DM muscles
and those reported by other Authors may be accounted for the
model used: measurements made in cultured cells or in animal
models which have been used to induce DM pathomechanism
may be different from results obtained in human muscle in vivo.
Moreover differences may exist between different muscle types
used.
It has been suggested that also the reduction of ZNF9/CNBP
expression in DM2 patients may explain some of the phenotypic
disparities between both types of DM. It has been shown that
reduction of ZNF9/CNBP levels is sufficient to produce multior-
gan symptoms resembling those of DM as observed in heterozy-
gous Znf92/2 knockout mice [72]. We have determined that
ZNF9/CNBP protein and mRNA levels in muscle biopsies of
biceps brachii from DM2 patients are significantly reduced
compared with non-DM2 individuals, including patients with
DM1. Our findings are consistent with recent reports of reduced
ZNF9/CNBP expression in DM2 [36,39,40] and these data
indicate that ZNF9/CNBP expression might play a role in
phenotypic differences between DM1 and DM2. However ZNF9/
CNBP protein appears to be equally expressed in the three DM2
phenotypic groups examined in our work, thus ZNF9/CNBP
expression levels do not explain the extreme variability of clinical
phenotype evident among DM2 patients. Indeed the expression of
ZNF9/CNBP protein in DM2-PS is similar to those observed in
DM2-PROMM and DM2-PDM despite paucisymptomatic pa-
tients show minor muscle histopathological alterations and the
frequency of abnormal isoforms of the genes analysed is lower than
in symptomatic patients.
This is the first study on a large number of muscle biopsies from
DM1 and DM2 patients analysed at histopathological and
biomolecular level. Our results indicate that CUGBP1 seems to
play a role in classic DM1 more evidently than in DM2 however
no definitive conclusions can be drawn due to the high
interindividual variability observed in the different parameters
analysed in this study. Nevertheless, it appears that the multisys-
temic disease spectrum and the phenotypic variability of DM
pathologies may not be explained only by spliceopathy thus
confirming that the molecular pathomechanism of DM is more
complex than that actually appreciate.
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